Rational engineering of L-asparaginase reveals importance of dual activity for cancer cell toxicity

Blood

Volumn 117, Issue 5, 2011, Pages 1614-1621

  Offman, Marc N ^a,b   Krol, Marcin ^a,c   Patel, Naina ^d   Krishnan, Shekhar ^d   Liu, JiZhong ^d   Saha, Vaskar ^d   Bates, Paul A ^a  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; GLUTAMINASE;

ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME ENGINEERING; GENE MUTATION; GENETIC ALGORITHM; HYDROGEN BOND; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

EID: 79551625096     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-298422     Document Type: Article

References (39)

1. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36(Database issue):D901-D906.
2. Bridgham JT, Ortlund EA, Thornton JW. An epistatic ratchet constrains the direction of glucocorticoid receptor evolution. Nature. 2009;461(7263):515-519.
3. Jiang L, Althoff EA, Clemente FR, et al. De novo computational design of retro-aldol enzymes. Science. 2008;319(5868):1387-1391.
4. Pavlova M, Klvana M, Prokop Z, et al. Redesigning dehalogenase access tunnels as a strategy for degrading an anthropogenic substrate. Nat Chem Biol. 2009;5(10):727-733.
5. Röthlisberger D, Khersonsky O, Wollacott AM, et al. Kemp elimination catalysts by computational enzyme design. Nature. 2008;453(7192):190-195.
6. Rishton GM. Failure and success in modern drug discovery: guiding principles in the establishment of high probability of success drug discovery organizations. Med Chem. 2005;1(5):519-527.
7. Labrou NE, Papageorgiou AC, Avramis VI. Structure-function relationships and clinical applications of L-asparaginases. Curr Med Chem. 2010;17(20):2183-2195.
8. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia. 2008;22(9):1665-1679.
9. Broome JD. Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effect. Nature. 1961;191:1114-1115.
10. Kidd JG, Sobin LH. The incorporation of l-asparagine-14C by lymphoma 6C3HED cells: its inhibition by guinea pig serum. Cancer Res. 1966;26(2):208-211.
11. Miller HK, Balis ME. Glutaminase activity of L-asparagine amidohydrolase. Biochem Pharmacol. 1969;18(9):2225-2232.
12. Krasotkina J, Borisova AA, Gervaziev YV, Sokolov NN. One-step purification and kinetic properties of the recombinant L-asparaginase from Erwinia carotovora. Biotechnol Appl Biochem. 2004;39(Pt 2):215-221.
13. Jarrar M, Gaynon PS, Periclou AP, et al. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer. 2006;47(2):141-146.
14. Miller HK, Salser JS, Balis ME. Amino acid levels following L-asparagine amidohydrolase (EC. 3.5.1.1) therapy. Cancer Res. 1969;29(1):183-187.
15. Ollenschläger G, Roth E, Linkesch W, Jansen S, Simmel A, Modder B. Asparaginase-induced derangements of glutamine metabolism: the pathogenetic basis for some drug-related side-effects. Eur J Clin Invest. 1988;18(5):512-516.
16. Story MD, Voehringer DW, Stephens LC, Meyn RE. L-asparaginase kills lymphoma cells by apoptosis. Cancer Chemother Pharmacol. 1993;32(2):129-133.
17. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer. 1976;37(1):220-228.
18. Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol. 1999;457:621-629.
19. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer. 1970;25(2):253-278.
20. Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med. 1969;281(19):1028-1034.
21. Warrell RP Jr, Chou TC, Gordon C, et al. Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adults. Cancer Res. 1980;40(12):4546-4551.
22. Warrell RP Jr, Arlin ZA, Gee TS, Chou TC, Roberts J, Young CW. Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia. Cancer Treat Rep. 1982;66(7):1479-1485.
23. Patel N, Krishnan S, Offman MN, et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug L-asparaginase. J Clin Invest. 2009;119(7):1964-1973.
24. Offman MN, Fitzjohn PW, Bates PA. Developing a move-set for protein model refinement. Bioinformatics. 2006;22(15):1838-1845.
25. Liu S, Zhang C, Zhou H, Zhou Y. A physical reference state unifies the structure-derived potential of mean force for protein folding and binding. Proteins. 2004;56(1):93-101. (Pubitemid 38720841)
26. Berman HM, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-242.
27. AMBER 9 [computer program]. San Francisco: University of California; 2006. Available from: http://ambermd.org/.
28. Kollman PA, Massova I, Reyes C, et al. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000;33(12):889-897.
29. Damborský J, Petrek M, Banas P, Otyepka M. Identification of tunnels in proteins, nucleic acids, inorganic materials and molecular ensembles. Biotechnol J. 2007;2(1):62-67.
30. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica. 2006;91(1):24-31.
31. Altschul SF, Madden TL, Schaffer AA, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 1997;25(17):3389-3402.
32. Aung HP, Bocola M, Schleper S, Rohm KH. Dynamics of a mobile loop at the active site of Escherichia coli asparaginase. Biochim Biophys Acta. 2000;1481(2):349-359.
33. Bradley P, Misura KM, Baker D. Toward high-resolution de novo structure prediction for small proteins. Science. 2005;309(5742):1868-1871.
34. Gao B, Wyttenbach T, Bowers MT. Hydration of protonated aromatic amino acids: phenylalanine, tryptophan, and tyrosine. J Am Chem Soc. 2009;131(13):4695-4701.
35. Derst C, Henseling J, Rohm KH. Engineering the substrate specificity of Escherichia coli asparaginase. II. Selective reduction of glutaminase activity by amino acid replacements at position 248. Protein Sci. 2000;9(10):2009-2017.
36. Swain AL, Jaskolski M, Housset D, Rao JK, Wlodawer A. Crystal structure of Escherichia coli L-asparaginase, an enzyme used in cancer therapy. Proc Natl Acad Sci U S A. 1993;90(4):1474-1478.
37. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104(49):19345-19350.
38. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979;254(8):2669-2676. (Pubitemid 9196102)
39. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427-433.